The biology of TNF blockade

Area of Science:

• Immunology
• Gastroenterology
• Rheumatology

Background:

• Rheumatoid arthritis and Crohn's disease are chronic inflammatory conditions causing significant patient disability.
• Increased production of Tumor Necrosis Factor (TNF) is a hallmark of these diseases.
• Anti-TNF biological therapies have revolutionized treatment but are not universally effective.

Purpose of the Study:

• To explore the mechanisms of non-response to anti-TNF therapy in rheumatoid arthritis and Crohn's disease.
• To identify host factors influencing treatment efficacy and disease course.
• To detail potential adverse effects associated with anti-TNF agents.

Main Methods:

• Review of existing literature on anti-TNF therapy in inflammatory diseases.
• Analysis of host-related factors contributing to treatment outcomes.
• Examination of genetic influences, including TNF promoter polymorphisms and TNF receptor gene variations.

Main Results:

• Anti-TNF therapy is effective in approximately two-thirds of patients, but responses are often temporary.
• Non-response is associated with host cytokine response, disease phenotype, and antibody formation against anti-TNF agents.
• NOD2 defects do not correlate with non-response; TNF gene polymorphisms and receptor heterogeneity significantly impact outcomes.

Conclusions:

• Understanding host factors is crucial for predicting and managing anti-TNF therapy response.
• Genetic variations in TNF pathways play a key role in treatment efficacy and disease severity.
• Adverse effects of anti-TNF therapy require careful monitoring and management.